Jana Chavous, APRN
Acute Care · Tulsa, OKNPI 1942729546
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,407 of the $4,202 with a category attached, or 81.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,553, 3.3 times the $465 reported in 2021.
Across 139 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$654
- Johnson & Johnson$610
- Astellas Pharma US Inc$322
- Takeda Pharmaceuticals U.S.A., Inc.$315
- Novartis$301
- Lilly USA, LLC$273
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,40781%
- Education$79519%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $654 |
| Johnson & Johnson(2 entities) | 15 | $610 |
| Astellas Pharma US Inc | 4 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $315 |
| Novartis | 17 | $301 |
| Lilly USA, LLC | 6 | $273 |
| AbbVie | 10 | $208 |
| Incyte Corporation | 2 | $180 |
| Seagen Inc. | 3 | $154 |
| Pfizer | 7 | $129 |
| Amgen | 1 | $121 |
| Daiichi Sankyo Inc. | 5 | $105 |
| Sanofi | 4 | $93 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| AVEO Pharmaceuticals, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $62 |
| Genentech USA, Inc. | 3 | $59 |
| Genmab U.S., Inc. | 2 | $54 |
| Bristol Myers Squibb | 2 | $42 |
| Merck | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Geron Corporation | 2 | $33 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Bayer | 1 | $27 |
| Heron Therapeutics, Inc. | 2 | $24 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,202 in reported general payments places this provider in the 85th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 14 | $764 |
| Potassium Chloride | 22 | $454 |
| Prochlorperazine Maleate | 11 | $195 |
| Gabapentin | 23 | $161 |
| Mirtazapine | 11 | $155 |
Paid to pharmacies, not to this prescriber.
Other acute care in Tulsa
- Pavel BuzadzhiTulsa$26K
- Jerrie MoralesTulsa$15K
- Lisa ArmstrongTulsa$14K
- Ganna StarkeyTulsa$14K
- Jasmine ThompsonTulsa$12K
- Christina HulseyTulsa$9K
- Brandon KingTulsa$9K
- Christina OverlyTulsa$8K
- Brian HutchinsonTulsa$7K
- Mallory NealTulsa$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.